Francis deSouza

Illumina Announces New Innovative Partnerships, Along With New Groundbreaking Technologies at 2022 J.P. Morgan Healthcare Conference

Summary: 

Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.

Press Release

Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.

Illumina CEO Reflects on the State of Genomics in 2021

Blog

By Francis deSouza

COVID-19 inflicted tremendous suffering in 2021, taking almost 3.5 million lives this year, more than died from HIV/AIDS, tuberculosis and malaria combined last year. We will never forget the loss and pain of this year. But 2021 will also be remembered for the heroic actions of many, and the major medical breakthroughs that were accelerated by the extreme urgency of the pandemic.

Illumina Is One of the 2021 TIMES Most Influential Companies

Article

The pandemic is providing a stage for demonstrating what genome sequencing can do for infectious diseases like COVID-19 as well as other conditions like cancer.  When it comes to public health, genetic sequencing isn’t as routine a part of disease management as it should be. The pandemic has brought us into the 21st century, into the era of biology and the era of the genome.  But many parts of the world don’t have such resources to purchase Illumina machines,—not to mention to analyze and interpret the results.

Subscribe to Francis deSouza